Expert consensus guideline on cholesterol-lowering strategies for Chinese population with dyslipidemia and ASCVD

Photo by Enayet Raheem / Unsplash

Frontiers in Medicine Published May 24, 2026 Medically reviewed May 24, 2026 DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Consider this expert consensus as guidance for initial cholesterol-lowering strategies in Chinese patients with dyslipidemia.

This document is an expert consensus guideline focused on initial cholesterol-lowering strategies for the Chinese population with dyslipidemia and atherosclerotic cardiovascular disease. The scope is to improve the prevention and management of dyslipidemia in this population. The authors synthesize expert opinion to provide practice guidance, but the guideline does not report specific pooled effect sizes, sample sizes, or primary outcome data.

The guideline does not detail a study population, intervention comparator, or adverse events, as these were not reported. The authors note that the document is a consensus, not a primary trial or systematic review, and its recommendations are based on expert synthesis rather than new trial data.

Key limitations include the lack of reported sample size, follow-up duration, and specific outcome data. The guideline's practice relevance is to inform initial strategies for dyslipidemia management in China, but its recommendations should be interpreted with caution due to the absence of reported quantitative evidence.

Clinicians should consider this guideline as one source of expert opinion for Chinese patients with dyslipidemia and ASCVD, recognizing that it does not provide new trial-level evidence.

Study Details

Study typeGuideline

EvidenceLevel 5

PublishedMay 2026

View Original Abstract ↓

It has been confirmed that cholesterol-lowering therapy, particularly the reduction of low-density lipoprotein cholesterol (LDL-C) levels, represents the most effective measure for decreasing the incidence of atherosclerotic cardiovascular disease and related cardiovascular events. Previous studies have shown that active reduction of cholesterol levels significantly increases the goal attainment rate of LDL-C and improves clinical outcomes. Although many cholesterol-lowering medications are currently available in clinical practice and the cholesterol lowering treatment status has improved, the real-world cholesterol management in China, especially the goal attainment rate of LDL-C, is not satisfactory. This issue is closely related to the selection of initial cholesterol-lowering treatment strategies. Furthermore, clinical research has demonstrated that the safety and adherence of cholesterol-lowering therapy are also critical factors influencing treatment effectiveness. In response, the National Cardiovascular Disease Expert Committee Cardiovascular Metabolic Medicine Professional Committee has organized domestic experts to systematically and comprehensively review methods and scientific choices for initiating cholesterol-lowering therapy in the Chinese population and developed a Chinese expert consensus on the selection of initial cholesterol-lowering strategies based on current evidence. It aims to propose optimized initial treatment regimens tailored to individual characteristics, thereby further improving the prevention and management of dyslipidemia in Chinese population.